ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,224.10
0.03%
Dow Jones
39,483.44
-0.07%
US Dollar vs MXN
16.8106
0.17%
Brent Oil
82.895
0.62%
Bitcoin
63,174.63
2.81%
Registration Strip Icon for discussion Regístrate para interactuar en nuestros foros activos para discutir con inversores de ideas afines.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. BiondVax Pharmaceuticals Ltd (BVXV)

  7. BiondVax Pharmaceuticals Ltd (BVXV) Noticias

BVXV

BiondVax Pharmaceuticals (BVXV)

BiondVax Pharmaceuticals Ltd
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:BVXV
FechaHoraFuenteTítuloSímboloCompañía
30/04/202415:06Edgar (US Regulatory)Form NT 20-F - Notification of inability to timely file Form 20-FNASDAQ:BVXVBiondVax Pharmaceuticals Ltd
16/04/202416:27Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:BVXVBiondVax Pharmaceuticals Ltd
10/04/202406:00PR Newswire (US)Scinai to showcase its novel biological local therapeutic for Plaque Psoriasis at Dermatology Drug Development Summit together with Prof. Michael Schön of UMGNASDAQ:BVXVBiondVax Pharmaceuticals Ltd
12/03/202415:17Edgar (US Regulatory)Form SC 13D - General statement of acquisition of beneficial ownershipNASDAQ:BVXVBiondVax Pharmaceuticals Ltd
12/03/202407:00PR Newswire (US)Scinai leadership to attend BIO-Europe Spring 2024NASDAQ:BVXVBiondVax Pharmaceuticals Ltd
13/02/202406:00PR Newswire (US)Scinai Welcomes Liat Halpert as Head of Business Development and SalesNASDAQ:BVXVBiondVax Pharmaceuticals Ltd
04/01/202415:01PR Newswire (US)Scinai Immunotherapeutics Announces Closing of Exercise of Outstanding Warrants for $1.69 Million in Gross ProceedsNASDAQ:BVXVBiondVax Pharmaceuticals Ltd
20/11/202306:30PR Newswire (US)Scinai Immunotherapeutics Regains Compliance with Nasdaq's Stockholders' Equity RuleNASDAQ:BVXVBiondVax Pharmaceuticals Ltd
07/09/202316:27Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:BVXVBiondVax Pharmaceuticals Ltd
06/09/202305:00GlobeNewswire Inc.BiondVax Pharmaceuticals Ltd. Rebrands as Scinai Immunotherapeutics Ltd. to Reflect New Focus on Development of Novel Inflammation and Immunology (I&I) Biological TherapeuticsNASDAQ:BVXVBiondVax Pharmaceuticals Ltd
28/08/202315:01Edgar (US Regulatory)Form 424B2 - Prospectus [Rule 424(b)(2)]NASDAQ:BVXVBiondVax Pharmaceuticals Ltd
27/08/202323:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:BVXVBiondVax Pharmaceuticals Ltd
18/08/202315:16Edgar (US Regulatory)Form F-3 - Registration statement by foreign private issuersNASDAQ:BVXVBiondVax Pharmaceuticals Ltd
18/08/202309:07Edgar (US Regulatory)Form 6-K/A - Report of foreign issuer [Rules 13a-16 and 15d-16]: [Amend]NASDAQ:BVXVBiondVax Pharmaceuticals Ltd
11/08/202308:00GlobeNewswire Inc.BiondVax Reports Second Quarter Financial Results and Provides Business UpdateNASDAQ:BVXVBiondVax Pharmaceuticals Ltd
01/08/202315:01GlobeNewswire Inc.Nasdaq Grants BiondVax Extension to Regain Compliance with Listing RulesNASDAQ:BVXVBiondVax Pharmaceuticals Ltd
11/07/202307:17GlobeNewswire Inc.IBN Announces Latest Episode of The Bell2Bell Podcast featuring Amir Reichman, CEO of BiondVax Pharmaceuticals Ltd.NASDAQ:BVXVBiondVax Pharmaceuticals Ltd
08/06/202315:31Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:BVXVBiondVax Pharmaceuticals Ltd
05/06/202306:00GlobeNewswire Inc.BiondVax signs exclusive license agreement for development and commercialization of a novel anti-IL-17 antibody for treatment of autoimmune and inflammatory diseases including psoriasisNASDAQ:BVXVBiondVax Pharmaceuticals Ltd
15/05/202316:05Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:BVXVBiondVax Pharmaceuticals Ltd
17/04/202315:52Edgar (US Regulatory)Securities Registration: Employee Benefit Plan (s-8)NASDAQ:BVXVBiondVax Pharmaceuticals Ltd
17/04/202315:25GlobeNewswire Inc.BiondVax Files FY 2022 Financial Statements and Annual Report on Form 10-K and Provides Business UpdateNASDAQ:BVXVBiondVax Pharmaceuticals Ltd
03/04/202308:13Edgar (US Regulatory)Notification That Annual Report Will Be Submitted Late (nt 10-k)NASDAQ:BVXVBiondVax Pharmaceuticals Ltd
16/03/202312:10GlobeNewswire Inc.BiondVax to Present at BIO-Europe SpringNASDAQ:BVXVBiondVax Pharmaceuticals Ltd
03/03/202313:07GlobeNewswire Inc.IBN Announces ‘Test. Optimize. Scale.’ Interview with BiondVax Pharmaceuticals Ltd. CEO Amir Reichman Discussing De-Risked Development Pipeline and Strategic Partnerships with Premier European Research InstitutesNASDAQ:BVXVBiondVax Pharmaceuticals Ltd
02/02/202313:15GlobeNewswire Inc.BiondVax Presenting at BIO CEO & Investor ConferenceNASDAQ:BVXVBiondVax Pharmaceuticals Ltd
23/01/202308:45Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:BVXVBiondVax Pharmaceuticals Ltd
23/01/202307:17Edgar (US Regulatory)Amended Statement of Beneficial Ownership (3/a)NASDAQ:BVXVBiondVax Pharmaceuticals Ltd
23/01/202305:25GlobeNewswire Inc.BiondVax’s Innovative Inhaled Anti-SARS-CoV-2 NanoAb Virtually Prevented Illness When Administered Prophylactically in Preclinical In Vivo StudyNASDAQ:BVXVBiondVax Pharmaceuticals Ltd
06/01/202306:15GlobeNewswire Inc.BiondVax’s Innovative Inhaled COVID-19 Therapy Virtually Eliminated SARS-COV-2 Virus in Preclinical In Vivo StudyNASDAQ:BVXVBiondVax Pharmaceuticals Ltd
 Showing the most relevant articles for your search:NASDAQ:BVXV

Su Consulta Reciente

PM
XAUUSD
Gold vs US Dollar
NYSE
KO
Coca Cola
NASDAQ
MSFT
Microsoft
COIN
BTCUSD
Bitcoin
USI
USTECH100
US Tech 100
CCOM
OILBRENT
Brent Oil
COIN
ETHUSD
Ethereum
CCOM
US30
US 30
AMEX
XLV
Health Care Select Sector
NYSE
AXP
American Express
NYSE
MCD
McDonalds
FX
USDMXN
US Dollar vs MXN
NYSE
NKE
Nike
NYSE
BAC
Bank of America
CCOM
US500
US 500
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados